Search Results - Marissa F. Dockendorf

Effects of CYP3A4 and P-glycoprotein inhibition or induction on the pharmacokinetics of ubrogepant in healthy adults: Two phase 1, open-label, fixed-sequence, single-center, crosso... by Abhijeet Jakate, Ramesh Boinpally, Matthew Butler, Wendy Ankrom, Marissa F Dockendorf, Antonia Periclou

Connect to this object online.

Digitally Enabled, Patient‐Centric Clinical Trials: Shifting the Drug Development Paradigm by Marissa F. Dockendorf, Bryan J. Hansen, Kevin P. Bateman, Matthew Moyer, Jyoti K. Shah, Lisa A. Shipley

Connect to this object online.

Safety, Tolerability, and Pharmacokinetics of the β‐Site Amyloid Precursor Protein‐Cleaving Enzyme 1 Inhibitor Verubecestat (MK‐8931) in Healthy Elderly Male and Female Subjects... by Mark Forman, John Palcza, Jack Tseng, Julie A. Stone, Brittany Walker, Dennis Swearingen, Matthew D. Troyer, Marissa F. Dockendorf

Connect to this object online.

Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults by K. Chris Min, Walter K. Kraft, Phung Bondiskey, Francheska Colón‐González, Wen Liu, Jialin Xu, Deborah Panebianco, Lori Mixson, Marissa F. Dockendorf, Catherine Z. Matthews, Ramesh Boinpally

Connect to this object online.

Pharmacokinetic and pharmacodynamic assessments of atogepant in healthy male adults: Results from phase 1 studies by Ramesh Boinpally, Marleen Depré, Griet Van Lancker, Marissa F Dockendorf, Phung Bondiskey, Jean-Francois Denef, Tom Reynders, Catherine Zhou Matthews, K Chris Min, Jialin Xu, Joel M Trugman, Jan de Hoon

Connect to this object online.

Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males by Wendy Ankrom, Phung Bondiskey, Chi‐Chung Li, John Palcza, Wen Liu, Marissa F. Dockendorf, Catherine Matthews, Deborah Panebianco, Tom Reynders, John A. Wagner, Abhijeet Jakate, Sofie Mesens, Walter K. Kraft, Eugene E. Marcantonio

Connect to this object online.